Invos Global Investors
Investors

AI DRUG DISCOVERY PRIMED FOR REAL-WORLD DEVELOPMENT

Who we are

RELENTLESS MEDICINE DISCOVERY

We unite computation and RNAi to discover and develop life-transforming medicines. Our proprietary GalOmic™ RNAi platform and LLibra™ computational engine work together to accelerate discovery, reduce risk, and advance a pipeline of novel RNAi medicines toward patients.

[Testimonial]

The potential of Tangram as a biotech that fully integrates the latest advances in computation and artificial intelligence is clear. Ultimately, this leads to the development of life-transforming RNAi medicines for patients.

Ali Mortazavi, Chief Executive Officer

Invos Global About
Invos Company Overview
About our business

Company Overview

Find out more about Tangram Therapeutics. See the latest updates and developments in our business.

Download presentation

Latest News

Press Release

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

Apr 7, 2025

Press Release

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

May 7, 2025

Press Release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

June 7, 2025

Press Release

e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH

May 7, 2024

/

Latest News

Registered office:

Unit 4B, Level 4, 4 Kingdom Street, London W2 6PY
For all investor enquiries, please contact:

Email: support@invos.com